Literature DB >> 23332171

Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice.

Meaghan Morris1, Patricia Hamto, Anthony Adame, Nino Devidze, Eliezer Masliah, Lennart Mucke.   

Abstract

The microtubule-associated protein tau is expressed throughout the nervous system, most highly in neurons but also in glial cells. Its functions in adult and aging mammals remain to be defined. Previous studies in mouse models found either protective or detrimental effects of genetic tau ablation. Though tau ablation prevented synaptic, network, and cognitive dysfunctions in several models of Alzheimer's disease and made mice more resistant to epileptic seizures, a recent study described a parkinsonian phenotype in aging Tau knockout mice. Here we tested cognition and motor functions in Tau(+/+), Tau(+/-), and Tau(-/-) mice at approximately 1 and 2 years of age. Tau ablation did not impair cognition and caused only minor motor deficits that were much more subtle than those associated with the aging process. Tau ablation caused a mild increase in body weight, which correlated with and might have contributed to some of the motor deficits. However, tau ablation did not cause significant dopaminergic impairments, and dopamine treatment did not improve the motor deficits, suggesting that they do not reflect extrapyramidal dysfunction.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23332171      PMCID: PMC3596503          DOI: 10.1016/j.neurobiolaging.2012.12.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  17 in total

1.  Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice.

Authors:  S Ikegami; A Harada; N Hirokawa
Journal:  Neurosci Lett       Date:  2000-02-04       Impact factor: 3.046

2.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

Review 3.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

4.  Place navigation impaired in rats with hippocampal lesions.

Authors:  R G Morris; P Garrud; J N Rawlins; J O'Keefe
Journal:  Nature       Date:  1982-06-24       Impact factor: 49.962

5.  Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

Authors:  Lars M Ittner; Yazi D Ke; Fabien Delerue; Mian Bi; Amadeus Gladbach; Janet van Eersel; Heidrun Wölfing; Billy C Chieng; MacDonald J Christie; Ian A Napier; Anne Eckert; Matthias Staufenbiel; Edna Hardeman; Jürgen Götz
Journal:  Cell       Date:  2010-07-22       Impact factor: 41.582

6.  Tau reduction prevents Abeta-induced defects in axonal transport.

Authors:  Keith A Vossel; Kai Zhang; Jens Brodbeck; Aaron C Daub; Punita Sharma; Steven Finkbeiner; Bianxiao Cui; Lennart Mucke
Journal:  Science       Date:  2010-09-09       Impact factor: 47.728

7.  Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice.

Authors:  Yaisa Andrews-Zwilling; Nga Bien-Ly; Qin Xu; Gang Li; Aubrey Bernardo; Seo Yeon Yoon; Daniel Zwilling; Tonya Xue Yan; Ligong Chen; Yadong Huang
Journal:  J Neurosci       Date:  2010-10-13       Impact factor: 6.167

8.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

9.  Rapid activation of astrocyte-specific expression of GFAP-lacZ transgene by focal injury.

Authors:  L Mucke; M B Oldstone; J C Morris; M I Nerenberg
Journal:  New Biol       Date:  1991-05

Review 10.  Comparative techniques for determining cellular iron distribution in brain tissues.

Authors:  D P Perl; P F Good
Journal:  Ann Neurol       Date:  1992       Impact factor: 10.422

View more
  54 in total

1.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 2.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

3.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

4.  Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging.

Authors:  Qiu-Lan Ma; Xiaohong Zuo; Fusheng Yang; Oliver J Ubeda; Dana J Gant; Mher Alaverdyan; Nicolae C Kiosea; Sean Nazari; Ping Ping Chen; Fatiha Nothias; Piu Chan; Edmond Teng; Sally A Frautschy; Greg M Cole
Journal:  J Neurosci       Date:  2014-05-21       Impact factor: 6.167

5.  Seizure resistance without parkinsonism in aged mice after tau reduction.

Authors:  Zhiyong Li; Alicia M Hall; Mark Kelinske; Erik D Roberson
Journal:  Neurobiol Aging       Date:  2014-05-09       Impact factor: 4.673

6.  Importance of tau in cognitive decline as revealed by developmental exposure to lead.

Authors:  K Wright; S W Bihaqi; A Lahouel; A Masoud; F Mushtaq; A Leso; A Eid; N H Zawia
Journal:  Toxicol Lett       Date:  2017-12-05       Impact factor: 4.372

Review 7.  Emerging Diagnostic and Therapeutic Strategies for Tauopathies.

Authors:  David Coughlin; David J Irwin
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

8.  Antisense reduction of tau in adult mice protects against seizures.

Authors:  Sarah L DeVos; Dustin K Goncharoff; Guo Chen; Carey S Kebodeaux; Kaoru Yamada; Floy R Stewart; Dorothy R Schuler; Susan E Maloney; David F Wozniak; Frank Rigo; C Frank Bennett; John R Cirrito; David M Holtzman; Timothy M Miller
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

Review 9.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 10.  Antisense oligonucleotides: treating neurodegeneration at the level of RNA.

Authors:  Sarah L DeVos; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.